Real-World Outcomes of Immune Checkpoint Inhibitors in Lung Cancer: A Study from a Middle-Income Nation - Top-Institutions - MDSpire

Real-World Outcomes of Immune Checkpoint Inhibitors in Lung Cancer: A Study from a Middle-Income Nation

  • By

  • Zineb Benbrahim

  • Oumaima Siyouri

  • Mohamed Fetohi

  • Nadia Benchakroun

  • Nabil Ismaili

  • Nssiba Bahra

  • Nabil Tachfouti

  • Brahim El Ghissassi

  • Fatima Zahra El M’Rabet

  • Rhizlane Belbaraka

  • Ali Tahri

  • Abdelkader Acharqi

  • Nawfel Mellas

  • January 26, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Cancer Immunotherapy

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Immunotherapy

  • #4

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Research
    • Clinical Trials
    • Health Disparities

  • #5

    Tata Memorial Centre
    Tata Memorial Centre

    Mumbai, Maharashtra

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Global Oncology

Original Source(s)

Real-World Outcomes of Immune Checkpoint Inhibitors in Lung Cancer: A Study from a Middle-Income Nation

  • by Zineb Benbrahim, Oumaima Siyouri, Mohamed Fetohi, Nadia Benchakroun, Nabil Ismaili, Nssiba Bahra, Nabil Tachfouti, Brahim El Ghissassi, Fatima Zahra El M’Rabet, Rhizlane Belbaraka, Ali Tahri, Abdelkader Acharqi, Nawfel Mellas

  • January 26, 2026

Related Content

Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, volume III

Imaging features of lung cancer with cystic airspaces: clinical utility, challenges, and perspectives

Tumor immune microenvironment in non-small cell lung cancer progression